Company: IMCR
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001671927-25-000006
Chunk: 86

Company: Immunocore Holdings plc
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1A
Chunk 86
---
 market acceptance among physicians, patients and healthcare payors.

KIMMTRAK, and other product candidates that we may develop or acquire, may not attain or maintain market acceptance among physicians, patients, healthcare payors or the medical community, even if they receive marketing approval by relevant authorities. We believe that the degree of continued market acceptance and our ability to continue to generate revenues from KIMMTRAK will depend on a number of factors, including:

•timing of competitive medicines;

•continued efficacy and safety of KIMMTRAK;

•continued projected growth of the markets in which KIMMTRAK competes;

•the extent to which physicians diagnose and treat the conditions that KIMMTRAK is approved to treat;

•prevalence and severity of any side effects;

•if and when we are able to obtain regulatory approvals for additional indications for KIMMTRAK;

•continued acceptance by patients, physicians and applicable specialists;

•availability of, and ability to maintain, coverage and adequate reimbursement and pricing from government and other third-party payors;

•potential or perceived advantages or disadvantages of KIMMTRAK over alternative treatments, including cost of treatment and relative convenience and ease of administration;

•strength of sales, marketing and distribution support;

•the price of KIMMTRAK, both in absolute terms and relative to alternative treatments;

•impact of past and limitation of future medicine price increases;

•our ability to maintain a continuous supply of KIMMTRAK for commercial sale;

•the effect of current and future healthcare laws;

•disruptions caused by health pandemics or epidemics, including the extent to which physicians and patients delay visits or writing or filling prescriptions for KIMMTRAK;

•the performance of third-party distribution partners, over which we have limited control; and

•medicine labeling or medicine insert requirements of the FDA or other regulatory authorities

41

Table of Contents

Our ability to grow KIMMTRAK sales will be affected by the success of our sales, access, marketing and medical strategies. If KIMMTRAK or any other products that we may seek approval for, or acquire, fail to attain, or fail to maintain, market acceptance, we may not be able to generate significant revenue to sustain profitability, which would have a material adverse effect on our business, results of operations, financial condition and prospects (including,